Download PDFPDF
Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Can the UK Hib Experience Provide Lessons for Developing Countries?
    • Linda R Ojo, Project Coordinator, The Hib Initiative
    • Other Contributors:
      • Adam L. Cohen and Rana Hajjeh.

    We read with interest the encouraging article by Ladhani et al (August 2008) demonstrating the decline in Haemophilus influenzae type b (Hib) disease in the United Kingdom (UK) following introduction of a booster dose.(1) As an increasing number of developing countries are introducing Hib vaccine into their routine immunization programs, it remains to be seen whether a booster dose is needed in these countries as well....

    Show More
    Conflict of Interest:
    None declared.